CIOMS WORKING GROUP XII Benefit-Risk Balance for Medicinal Products (Update of CIOMS IV)

Participants as at February 2020

Patrick Caubel, Pfizer
Guacira Corrêa de Matos, ANVISA, Brazil
Stephen J.W. Evans, London School of Hygiene & Tropical Medicine, UK
Scott Evans, Milken Institute School of Public Health, George Washington University, USA
Richard Forshee, FDA CBER, USA
Stewart Geary, EISAI
Sergei Glagolev, Roszdravnadzor, Russian Federation
Takahiro Goto, WHO
Sanna Hill, CIOMS
Vicky Hogan, Health Canada, Canada
Karen Kaplan,* MSD
Sara Khosrovani, Medicines Evaluation Board, Netherlands
Noriaki Kitami, PMDA, Japan
Leila Lackey, FDA CDER, USA
Hussein Laljee,* Gilead
Hervé Le Louet, CIOMS
Shahrul Mt-Isa, MSD
Leo Plouffe, Bayer
George Quartey, Roche
Lembit Rägo, CIOMS
Cheryl Renz, AbbVie
Tomas Salmonson, Former Chair CHMP
Stephanie Storre, Swissmedic
Sabine Straus, Medicines Evaluation Board, Netherlands
Stephanie Tcherny-Lessenot, Sanofi
Steffen Thistrup, University of Copenhagen/Copenhagen Centre of Regulatory Science
Panos Tsintis, CIOMS
Mariko Tsukuda, PMDA, Japan
Sebastian Vulcu, Boehringer-Ingelheim
Julie Williams, Medicines and Healthcare Products Regulatory Agency, UK
Hong Yang,* FDA CBER, USA
Qun-Ying Yue, Uppsala Monitoring Centre, Sweden
Xi Sherry Zhang, Gilead

* Designates alternate members who will participate in Working Group meetings in case the member from the same institution cannot attend.